Suven Life Sciences Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
181
- Stock Symbol
-
530239
- Share Price
-
$2.89
- (As of Friday Closing)
Suven Life Sciences General Information
Description
Suven Life Sciences Ltd is an India-based clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India, the USA, Europe and the rest of the world. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
Contact Information
Website
www.suven.comCorporate Office
- 6th Floor, SDE Serene Chambers
- Avenue-7, Road Number 5, Banjara Hills
- Hyderabad, Telangana 500034
- India
Corporate Office
- 6th Floor, SDE Serene Chambers
- Avenue-7, Road Number 5, Banjara Hills
- Hyderabad, Telangana 500034
- India
Suven Life Sciences Stock Performance
As of 20-Nov-2026, Suven Life Sciences’s stock price is $2.89. Its current market cap is $815M with 283M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.89 | $2.95 | $1.33 - $4.24 | $815M | 283M | 43.4K | -$0.08 |
Suven Life Sciences Financials Summary
As of 30-Sep-2026, Suven Life Sciences has a trailing 12-month revenue of $981K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 923,442 | 342,366 | 268,894 | 237,217 |
| Revenue | 981 | 805 | 787 | 1,412 |
| EBITDA | (18,501) | (31,101) | (18,988) | (13,993) |
| Net Income | (19,415) | (31,273) | (19,010) | (12,693) |
| Total Assets | 52,724 | 66,158 | 15,804 | 34,164 |
| Total Debt | 1,668 | 1,769 | 0 | 85 |
Suven Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Suven Life Sciences Comparisons
Industry
Financing
Details
Suven Life Sciences Competitors (17)
One of Suven Life Sciences’s 17 competitors is Zydus Lifesciences, a Corporation company based in Ahmedabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Sun Pharmaceutical Industries | Corporation | Mumbai, India | ||||
| Jubilant Pharmova | Corporation | Noida, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India |
Suven Life Sciences Patents
Suven Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026146402-A1 | Pyrazolo and triazolopyridine derivatives as muscarinic m4 receptor positive allosteric modulators (m4 pams) | Pending | 30-Dec-2024 | ||
| WO-2026047494-A1 | 2-amino-pyrimidine derivatives as muscarinic m4 receptor positive allosteric modulators (m4 pams) | Pending | 26-Aug-2024 | ||
| AU-2024409574-A1 | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) | Pending | 22-Dec-2023 | ||
| EP-4828664-A1 | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) | Pending | 22-Dec-2023 | ||
| WO-2025134078-A1 | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) | Inactive | 22-Dec-2023 | A61P25/16 |
Suven Life Sciences Signals
Suven Life Sciences ESG
Risk Overview
Risk Rating
Updated October, 31, 2023
37.45 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,216
Rank
Percentile
Pharmaceuticals
Industry
of 921
Rank
Percentile
Pharmaceuticals
Subindustry
of 452
Rank
Percentile
Suven Life Sciences FAQs
-
When was Suven Life Sciences founded?
Suven Life Sciences was founded in 1989.
-
Where is Suven Life Sciences headquartered?
Suven Life Sciences is headquartered in Hyderabad, India.
-
What is the size of Suven Life Sciences?
Suven Life Sciences has 181 total employees.
-
What industry is Suven Life Sciences in?
Suven Life Sciences’s primary industry is Pharmaceuticals.
-
Is Suven Life Sciences a private or public company?
Suven Life Sciences is a Public company.
-
What is Suven Life Sciences’s stock symbol?
The ticker symbol for Suven Life Sciences is 530239.
-
What is the current stock price of Suven Life Sciences?
As of 20-Nov-2026 the stock price of Suven Life Sciences is $2.89.
-
What is the current market cap of Suven Life Sciences?
The current market capitalization of Suven Life Sciences is $815M.
-
What is Suven Life Sciences’s current revenue?
The trailing twelve month revenue for Suven Life Sciences is $981K.
-
Who are Suven Life Sciences’s competitors?
Zydus Lifesciences, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, Jubilant Pharmova, and Aurobindo Pharma are some of the 17 competitors of Suven Life Sciences.
-
What is Suven Life Sciences’s annual earnings per share (EPS)?
Suven Life Sciences’s EPS for 12 months was -$0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process